876918-32-0

Basic information

• Product Name: Boronic acid, [3-cyano-4-(2-methylpropoxy)phenyl]-
• CAS NO: 876918-32-0
• Molecular Formula: C11H14BNO3
• Molecular Weight: 219.048
• Mol File: 876918-32-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Boronic acid, [3-cyano-4-(2-methylpropoxy)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Boronic acid, [3-cyano-4-(2-methylpropoxy)phenyl]-(876918-32-0)
• EPA Substance Registry System: Boronic acid, [3-cyano-4-(2-methylpropoxy)phenyl]-(876918-32-0)

Safety Data

• Hazardous Substances Data: 876918-32-0(Hazardous Substances Data)

Upstream product

• 222315-01-7 5-bromo-2-isobutoxybenzaldehyde 
• 1761-61-1 5-bromosalicyclaldehyde 
• 876918-26-2 5-bromo-2-isobutoxy-benzonitrile 
• 5419-55-6 Triisopropyl borate 

Downstream Products

• 160844-75-7 2-(3-cyano-4-isobutyloxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester 
• 144060-53-7 febuxostat 

Relevant articles and documents

PROCESS AND INTERMEDIATES FOR THE PREPARATION OF SUBSTITUTED 2-ARYLTHIAZOLE CARBOXYLIC ACIDS

The present invention relates to processes and intermediates for the preparation of derivatives of 2-arylthiazole such as Febuxostat and its analogs. Febuxostat which is an inhibitor of xanthine oxidase, is used for the treatment of chronic hyperuricaemia

REMEDY OR PREVENTIVE FOR DIGESTIVE ULCER

An object of the present invention is to provide an agent for treating or preventing digestive ulcer that is effective even to ulcer of small intestine and others, for which gastric acid secretion inhibitors such as proton pump inhibitors are ineffective, and is superior to allopurinol in the efficaciousness and the safety. The pharmaceutical composition of the present invention comprising a non-purine xanthine oxidase inhibitor as the active ingredient is useful as an agent for treating or preventing ulcer that forms in digestive tracts by the attack of gastric acid, pepsin, stress, Helicobacter pylori bacteria, NSAID, etc. In particular, it is useful as an ulcer remedy heretofore unknown in the art as it is effective even for ulcer in small intestine for which gastric/duodenal ulcer remedies that inhibit gastric acid secretion such as proton pump inhibitors are ineffective.

2-PHENYLPYRIDINE DERIVATIVE

The present invention relates to a novel 2-phenylpyridine derivative or a salt thereof, wherein the pyridine ring is substituted with a carboxyl group or the like and the benzene ring has an electron-withdrawing group such as a cyano group and an electron-donating group such as a substituted alkoxy group at the same time. Since the compound of the invention has good xanthine oxidase-inhibitory action and uric acid-lowering action and does not have a structure derived from nucleic acid, the compound has advantages of high safety and excellent effects as compared with conventional compounds and is useful as a therapeutic or preventive agent for hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy, or the like.